The Asia Pacific Psoriasis Drugs Market Size is expected to reach USD 1.6 billion by 2024 from USD 1.1 billion in 2019, growing at a CAGR of 8.24% during the forecast period 2019-2024.
Psoriasis is a noncommunicable inflammatory skin condition that alters the life cycle of skin cells by speeding up the growth of cells on the surface of the skin. The rapid development of cells produces thick, silvery scales, and makes the skin red, dry, flaky, and itchy. Currently, no permanent cure is available for the disease, however, preventative measures can be adopted to slow down the growth of skin cells on the surface of the skin. Psoriasis can be treated either with pharmaceuticals or biopharmaceuticals therapies through the topical and systemic process.
These medications administered either by applying on the skin, or consumed orally, or through injections specifically block parts of immune system process by specifically targeting Tumour Necrosis Factor (TNF), Phosphodiesterase Type 4 (PDE4), Interleukin, among others.
The growth of Psoriasis Drugs market is majorly driven by factors such as rising healthcare expenditure, the introduction of a novel and more efficient drug, and expected entry of late-stage products. The key restraints of the market are a high cost involved in drug development, patent expiry of brand name drugs, and low efficacy of the product. Additionally, Psoriasis is not very prevalent in Asia-Pacific reason further restricting the growth for the product.
Asia Pacific Psoriasis Drugs Market has been segmented and sub-segmented into the following categories:
Top Companies dominating the Asia Pacific Psoriasis Drugs Market Profiled in the Report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Pfizer Inc (USA), Merck and Co. Inc (USA), Celgene Corporation (USA), Janssen Biotech Inc (USA), Stiefel Laboratories Inc (USA), Takeda Pharmaceutical Company Limited (Japan), Amgen (USA), and AbbVie (USA).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Type
5.1.1 Introduction
5.1.2 Pharmaceuticals
5.1.3 Biopharmaceuticals
5.1.4 Y-o-Y Growth Analysis, By Drug Type
5.1.5 Market Attractiveness Analysis, By Drug Type
5.1.6 Market Share Analysis, By Drug Type
5.2 Route of Administration
5.2.1 Introduction
5.2.2 Topical
5.2.3 Systemic
5.2.3.1 Oral
5.2.3.2 Intravenous
5.2.3.3 Other
5.2.4 Y-o-Y Growth Analysis, By Route of Administration
5.2.5 Market Attractiveness Analysis, By Route of Administration
5.2.6 Market Share Analysis, By Route of Administration
5.3 Target
5.3.1 Introduction
5.3.2 Tumour Necrosis Factor (TNF)
5.3.3 Phosphodiesterase Type 4 (PDE4)
5.3.4 Interleukin
5.3.5 Others
5.3.6 Y-o-Y Growth Analysis, By Target
5.3.7 Market Attractiveness Analysis, By Target
5.3.8 Market Share Analysis, By Target
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type
6.1.3.4 By Application
6.1.3.5 By Indication
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Type
6.1.4.4 By Application
6.1.4.5 By Indication
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Type
6.1.5.4 By Application
6.1.5.5 By Indication
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Johnson & Johnson
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis International AG
8.3 Pfizer Inc
8.4 Merck and Co. Inc
8.5 Celgene Corporation
8.6 Janssen Biotech Inc
8.7 Stiefel Laboratories Inc
8.8 Takeda Pharmaceutical Company Limited
8.9 Amgen
8.10 AbbVie
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
